pq912
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02190708)
Timeline
Indications
Mechanism of action
- Glutaminyl-peptide cyclotransferaseINHIBITOR
QPCT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pq912
- pq912
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04498650 | Phase 2 | Jul 6, 2020 | Free University of Amsterdam, Nordic Bioscience, Vivoryon Therapeutics AG |
| NCT03919162 | Phase 2 | Jan 31, 2020 | National Institute on Aging (NIA), Vivoryon Therapeutics |
| NCT02389413 | Phase 2 | Mar 1, 2015 | Free University of Amsterdam, Utrecht University, Vivoryon Therapeutics |
| NCT02190708 | Phase 1 | Jun 1, 2014 | Covance, Vivoryon Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vivoryon Therapeutics | For profit | 3 | 3 | 2 | 2014 |
| Free University of Amsterdam | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Covance | For profit | 1 | 0 | 1 | 2014 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2020 |
| Nordic Bioscience | For profit | 1 | 0 | 1 | 2020 |
| Utrecht University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Vivoryon Therapeutics AG | For profit | 1 | 1 | 1 | 2020 |
7 organizations
Page 1 / 1